HER2/neu and cd3 expression in breast cancer associated with diabetes

Breast cancer is one of the most common neoplasms globally, being responsible for a high mortality rate, especially in the presence of comorbidities such as diabetes mellitus (DM). In this context, molecular markers such as CD3 and HER2/neu play an essential role. CD3 is a crucial protein for the function and activation of T cells, playing a central role in antitumor immunity. Similarly, the HER2/neu receptor, a member of the epidermal growth factor receptor (EGFR) family, is directly involved in processes of cellular proliferation, angiogenesis and tumor aggressiveness in breast cancer. The aim of this study was to evaluate the expression of CD3 and HER2/neu markers in NST (non-special type) breast carcinomas in patients with and without type 2 DM. The analysis focuses on correlating the expression levels of these markers with the presence of diabetes mellitus and the clinicopathological characteristics of the tumors.